Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway.
City of Oslo Health Agency, Municipality of Oslo, Oslo, Norway.
Trials. 2024 Sep 13;25(1):612. doi: 10.1186/s13063-024-08442-w.
Polypharmacy and inappropriate drug use are associated with adverse health outcomes in older people. Collaborative interventions between geriatricians and general practitioners have demonstrated effectiveness in improving clinical outcomes for complex medication regimens in home-dwelling patients. Since 2012, Norwegian municipalities have established municipal in-patient acute care (MipAC) units, designed to contribute towards reducing the number of hospital admissions. These units predominantly serve older people who typically benefit from multidisciplinary approaches. The primary objective of this study is to evaluate the effect of cooperative medication reviews conducted by MipAC physicians, supervised by geriatricians, and in collaboration with general practitioners, on health-related quality of life and clinical outcomes in MipAC patients ≥ 70 years with polypharmacy. Additionally, the study aims to assess the carbon footprint of the intervention.
This is a randomized, single-blind, controlled superiority trial with 16 weeks follow-up. Participants will be randomly assigned to either the control group, receiving usual care at the MipAC unit, or to the intervention group which in addition receive clinical medication reviews that go beyond what is considered usual care. The medication reviews will evaluate medication appropriateness using a structured but individualized framework, and the physicians will receive supervision from geriatricians. Following the clinical medication reviews, the MipAC physicians will arrange telephone meetings with the participants' general practitioners to combine their assessments in a joint medication review. The primary outcome is health-related quality of life as measured by the 15D instrument. Secondary outcomes include physical and cognitive functioning, oral health, falls, admissions to healthcare facilities, and mortality.
This study aims to identify potential clinical benefits of collaborative, clinical medication reviews within community-level MipAC units for older patients with polypharmacy. The results may offer valuable insights into optimizing patient care in comparable municipal healthcare settings.
The study was registered prospectively on ClinicalTrials.gov 30.08.2023 with identifier NCT06020391.
老年人同时服用多种药物和不合理用药与不良健康结果相关。老年病医生和全科医生之间的协作干预措施已被证明可改善居家患者复杂药物治疗方案的临床结局。自 2012 年以来,挪威各市政府设立了市立住院急性护理(MipAC)病房,旨在减少住院人数。这些病房主要服务于老年人,他们通常受益于多学科方法。本研究的主要目的是评估 MipAC 医生进行合作药物审查的效果,这些医生由老年病医生监督,并与全科医生合作,对患有多种药物的 MipAC 患者(年龄≥70 岁)的健康相关生活质量和临床结局的影响。此外,该研究旨在评估干预措施的碳足迹。
这是一项随机、单盲、对照优势试验,随访 16 周。参与者将被随机分配到对照组,在 MipAC 病房接受常规护理,或干预组,除了接受常规护理之外,还接受临床药物审查。药物审查将使用结构化但个性化的框架评估药物的适宜性,医生将接受老年病医生的监督。在进行临床药物审查后,MipAC 医生将与患者的全科医生进行电话会议,以在联合药物审查中结合他们的评估。主要结局是通过 15D 工具测量的健康相关生活质量。次要结局包括身体和认知功能、口腔健康、跌倒、入住医疗机构和死亡率。
本研究旨在确定社区级 MipAC 病房内合作临床药物审查对患有多种药物的老年患者的潜在临床益处。结果可能为优化类似市立医疗保健环境中的患者护理提供有价值的见解。
该研究于 2023 年 8 月 30 日在 ClinicalTrials.gov 上进行了前瞻性注册,标识符为 NCT06020391。